Edwards Lifesciences (NYSE:EW) shared its ambitious growth trajectory as it transitions into a dedicated structural heart enterprise by 2025. This pivot follows the $4.2 billion divestment of its Critical Care division to BD, inciting a 3% global workforce reduction and revised earnings guidelines for the year.
In a recent briefing, Edwards unveiled advancements in its technology portfolio, spotlighting development catalysts in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT). The company further highlighted the enduring success of its Surgical segment and outlined promising prospects for Structural Heart Failure and Aortic Regurgitation (AR).
The firm has maintained its 2024 growth outlook between 8% and 10% and predicts a similar sales expansion for 2025 in constant currency terms, with projected adjusted earnings per share (EPS) between $2.40 and $2.50. TAVR sales are forecasted to range from $4.1 billion to $4.4 billion, aligned with a stable currency growth of 5% to 7%.
According to BTIG analysts Marie Thibault and Sam Eiber, Edwards’ sales expectations for 2025 fall between $5.6 billion and $6 billion, matching a consensus of $5.905 billion.
TAVR emerges as a pivotal growth catalyst, underlined by Edwards’ foundational TAVR initiatives. The company anticipates mid-year approval for early TAVR treatment indications. TMTT’s product lineup—including the Pascal, Evoque, and Sapien M3 systems—aims to generate $500 million to $530 million, signaling a 50% to 60% annual growth.
Looking ahead to 2026 and beyond, Edwards expects continued influence from an expanding suite of structural heart therapies.
“Today’s announcements mark a significant milestone for Edwards as we outline our strategic vision for 2025 and how our competent team is leveraging our focus on structural heart initiatives to impact more patients,” stated Bernard Zovighian, CEO of Edwards. “We foresee robust overall sales growth of 8 to 10 percent in the upcoming year, with tremendous potential for TAVR expansion. We remain staunchly committed to scientific advancement and optimizing care for aortic stenosis patients. Our TMTT vision has matured into a distinctive growth portfolio of technologies. In our Surgical branch, the global uptake of our premium Resilia products continues to be robust.
“In the upcoming years, formidable company sales growth will be driven by significant catalysts with transformative potential for aortic stenosis treatment, including the Early TAVR and successful outcomes anticipated from the FDA-sanctioned PROGRESS pivotal trial. The TMTT portfolio will spearhead sustained rapid growth with Pascal, Evoque, and Sapien M3, while tackling new opportunities presented by AR and Structural Heart Failure.”